# Fate Therapeutics clinical trials: 25 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials with Fate Therapeutics as lead sponsor, 5 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Fate Therapeutics: 25 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/fate-therapeutics

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 2, 2026 | NCT07800871 | FT839 in Autoimmune Diseases | Fate Therapeutics | Phase 1/2 | Recruiting | ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA), Systemic Lupus... | 446 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07800871) |
| May 6, 2026 | NCT07570862 | A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis | Fate Therapeutics | Phase 2 | Recruiting | Lupus Nephritis, Systemic Lupus Erythematosus, SLE - Systemic Lupus Erythematosus, Lupus Nephritis - WHO Class III... | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07570862) |
| October 14, 2025 | NCT07216105 | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | Fate Therapeutics | Phase 1 | Recruiting | Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Endometrial Carcinoma, Head and Neck... | 119 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07216105) |
| March 13, 2024 | NCT06308978 | A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease | Fate Therapeutics | Phase 1 | Recruiting | Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM)... | 244 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06308978) |
| February 5, 2024 | NCT06241456 | FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors | Fate Therapeutics | Phase 1 | Recruiting | Advanced Solid Tumor | 351 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06241456) |
| July 18, 2023 | NCT05950334 | FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) | Fate Therapeutics | Phase 1 | Completed | Relapsed/Refractory B-Cell Lymphoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05950334) |
| July 6, 2023 | NCT05934097 | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | Fate Therapeutics | Phase 1 | Withdrawn | Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma... | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05934097) |
| May 27, 2022 | NCT05395052 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Fate Therapeutics | Phase 1 | Terminated | Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer... | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05395052) |
| January 10, 2022 | NCT05182073 | FT576 in Subjects With Multiple Myeloma | Fate Therapeutics | Phase 1 | Completed | Multiple Myeloma, Myeloma | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05182073) |
| October 6, 2021 | NCT05069935 | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Fate Therapeutics | Phase 1 | Terminated | Solid Tumor, Adult | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05069935) |
| November 16, 2020 | NCT04629729 | FT819 in Subjects With B-cell Malignancies | Fate Therapeutics | Phase 1 | Active not recruiting | Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04629729) |
| November 4, 2020 | NCT04614636 | FT538 in Subjects With Advanced Hematologic Malignancies | Fate Therapeutics | Phase 1 | Terminated | Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma, Myeloma | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04614636) |
| September 16, 2020 | NCT04551885 | FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Fate Therapeutics | Phase 1 | Terminated | Solid Tumor, Adult | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04551885) |
| January 29, 2020 | NCT04245722 | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | Fate Therapeutics | Phase 1 | Terminated | Lymphoma, B-Cell, Chronic Lymphocytic Leukemia | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04245722) |
| September 26, 2019 | NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | Fate Therapeutics | Observational | Terminated | Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04106167) |
| September 18, 2019 | NCT04093622 | Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy | Fate Therapeutics | Observational | Terminated | Hematological Malignancy | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04093622) |
| July 17, 2019 | NCT04023071 | FT516 in Subjects With Advanced Hematologic Malignancies | Fate Therapeutics | Phase 1 | Terminated | Acute Myelogenous Leukemia, B-cell Lymphoma | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04023071) |
| February 15, 2019 | NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | Fate Therapeutics | Phase 1 | Completed | Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR... | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03841110) |
| October 24, 2017 | NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | Fate Therapeutics | Phase 1 | Completed | HER2 Positive Gastric Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, EGFR Positive Solid Tumor... | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03319459) |
| April 19, 2016 | NCT02743351 | Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies | Fate Therapeutics | Phase 1/2 | Completed | Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Chronic... | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02743351) |
| February 3, 2015 | NCT02354443 | A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders | Fate Therapeutics | Phase 1 | Terminated | Metabolic Disorders | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02354443) |
| February 3, 2015 | NCT02354417 | A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies | Fate Therapeutics | Phase 1 | Terminated | Hematologic Malignancies | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02354417) |
| June 25, 2012 | NCT01627314 | The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic... | Fate Therapeutics | Phase 2 | Terminated | Hematologic Malignancies | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01627314) |
| February 7, 2012 | NCT01527838 | Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit | Fate Therapeutics | Phase 1 | Completed | Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease, Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML)... | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01527838) |
| April 29, 2009 | NCT00890500 | Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies. | Fate Therapeutics | Phase 1 | Completed | Hematologic Malignancies, Allogeneic Stem Cell Transplantation | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00890500) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 19 |
| Phase 1/2 | 2 |
| Phase 2 | 2 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Terminated | 11 |
| Completed | 7 |
| Recruiting | 5 |
| Withdrawn | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hematologic Neoplasms | 6 |
| Colorectal Neoplasms | 5 |
| Carcinoma, Non-Small-Cell Lung | 5 |
| Carcinoma, Renal Cell | 5 |
| Lymphoma | 5 |
| Carcinoma, Hepatocellular | 4 |
| Pancreatic Neoplasms | 4 |
| Melanoma | 4 |
| Breast Neoplasms | 4 |
| Head and Neck Neoplasms | 4 |
| Stomach Neoplasms | 4 |
| Lymphoma, B-Cell | 4 |
| Carcinoma, Merkel Cell | 4 |
| Leukemia, Myeloid, Acute | 4 |
| Squamous Cell Carcinoma of Head and Neck | 3 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 |
| Carcinoma, Transitional Cell | 3 |
| Lupus Erythematosus, Systemic | 3 |
| Leukemia | 2 |
| Carcinoma, Squamous Cell | 2 |
| Small Cell Lung Carcinoma | 2 |
| Uterine Cervical Neoplasms | 2 |
| Microsatellite Instability | 2 |
| Multiple Myeloma | 2 |
| Neoplasms, Plasma Cell | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Moving companies in the United States](https://specstream.ai/data/businesses/moving-companies/united-states)
- [IT companies in the United States](https://specstream.ai/data/businesses/it-companies/united-states)
- [Georgian restaurants in the United States](https://specstream.ai/data/businesses/georgian-restaurants/united-states)
- [Electrical wholesalers in the United States](https://specstream.ai/data/businesses/electrical-wholesalers/united-states)
- [Cleaning products suppliers in the United States](https://specstream.ai/data/businesses/cleaning-products-suppliers/united-states)
- [Bangladeshi restaurants in the United States](https://specstream.ai/data/businesses/bangladeshi-restaurants/united-states)
